Investment-blog.net: Stocks, Emerging markets, Bonds, Currencies and Commodities

Congratulations To Anyone Who Has Invest Delcath Systems Inc. (DCTH). Over 50% Jump Yesterday.

Nov 21, 2007 Market Outlook

Delcath Systems Inc. (DCTH)

U.S. Food and Drug Administration (FDA) has notified the Company that patient enrollment may resume in the Phase III and Phase II clinical trials of the Delcath System. Current and prospective clinical investigation sites have been notified that study accrual can be resumed immediately. This decision follows Delcath’s meeting with representatives of the U.S. Food and Drug Administration (FDA), along with the Principal Investigator at the National Cancer Institute (NCI).

http://biz.yahoo.com/bw/071120/20071120005642.html?.v=1

About Delcath Systems, Inc.

Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated organ and region specific delivery of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested with the drug Melphalan in a Phase III trial of patients with metastatic ocular and cutaneous melanoma in the liver, and a Phase II trial of patients with primary liver cancers and metastatic tumors in the liver from neuroendocrine cancers, adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion.Once again, Congratulations.

I will continuous to dig more stocks like this and hopefully more doubling can happen shortly.

GL

Did you like this? If so, please bookmark it, about it, and subscribe to the blog RSS feed.

Possibly Related Posts:

• Paulson Was Behind Bailout Martial Law Threat; Inhofe says Treasury Secretary made dire warnings in conference call on September 19th
• Depression? Oversold? Just the beginning? Close to the end? You will find zero guidance from quality analysts.
• A List of ETFs You Should Know In Stock Market
• Florida pension fund loses a quarter its value
• Good bye to U.S dollar. Say hello to Gold and Amero

Did you like this? If so, please bookmark it, about it, and subscribe to the blog RSS feed.